Amrubicin
Amrubicin is a Japanese anthracycline approved there in 2002 for small cell and non-small cell lung cancer, a standard second-line option for small cell lung cancer in Japan that failed to beat topotecan in a Western phase 3 trial and now serves as the comparator in global trials.
Overview
Sumitomo Dainippon's amrubicin was approved in Japan in 2002 for small cell and non-small cell lung cancer. Japanese trials established it as second-line treatment for relapsed small cell lung cancer, where response rates exceeded topotecan's, but the international ACT-1 phase 3 trial showed no overall survival advantage over topotecan and it was never approved in the United States or Europe. It remains in Japanese guidelines, and current phase 3 trials of new agents such as tarlatamab and ifinatamab deruxtecan use it as one of the standard comparator arms.
A fully synthetic anthracycline whose active metabolite amrubicinol poisons topoisomerase II; it causes less cardiotoxicity than doxorubicin in preclinical models. Connects to Topoisomerase II alpha (TOP2A).
1.Amrubicin slips into a pocket on Topoisomerase II alpha (TOP2A).
Approvals
| Region | Year | Indication |
|---|---|---|
| JP | 2002 | Small cell lung cancer and non-small cell lung cancer |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Amrubicin" OR ABSTRACT:"Amrubicin" OR TITLE:"Calsed" OR ABSTRACT:"Calsed" OR TITLE:"SM-5887" OR ABSTRACT:"SM-5887") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Amrubicin, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentABBV-706
Shares A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer, Non-small-cell lung cancer and the tag pipeline.
- TreatmentPirarubicin
Shares Topoisomerase II alpha (TOP2A), Cytotoxic chemotherapy and the tag pipeline.
- TreatmentAL8326
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
- TreatmentGlumetinib
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
- TreatmentAK117
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
- TreatmentVebreltinib
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
- TreatmentSSGJ-706
Shares Non-small-cell lung cancer and the tag pipeline.
- TreatmentIN10018
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.